@

COVID-19 Biomarker

covid article

Proteomics Research Blog

Enabling Precision Medicine

patient stratification for precision medicineProtein profiling is essential in modern biomedical research. The aim is improving patients' quality of life by utilizing molecular signatures to guide diagnosis and treatment.

At Sciomics, we consider ourselves scientists dedicated to improving medical care. We believe our exploratory proteomic and post-translational modification profiling platform drives significant advancements in Precision Medicine. By supporting other scientists with our expertise and by conducting our own research, we are utilizing our protein profiling expertise to the fullest.

Our Scientific Protein Profiling Services

We provide scientific high-content protein profiling services based on our antibody microarray platform. The analysis is based on either our fixed-contentarray portfolio (scioDiscover, scioCyto, scioCD) or customized antibody arrays. The protein abundance measurement of more than 1,400 proteins can be extended by a parallel analysis of their corresponding phosphorylation status (scioPhospho) or ubiquitination status (scioUbi). For your convenience and fast usability of the results, our service always includes an in-depth bioinformatic data analysis and a detailed scientific study report. Our protein analysis platform reduces the cost and attrition rate in your protein biomarker development as well as in pre-clinical evaluations of compounds through in-depth insights on the relevant level of proteins.

 

Main Advantages of Our Protein Profiling Platform 

  • High-content analysis: over 1400 proteins are analyzed in parallel

  • Broad coverage of key pathways and diseases

  • Widely applicable for biomarker discovery, mode-of-action analysis, disease mechanism studies etc.

  • A wide range of samples can be analyzed and data-integrated, such as plasma, serum, CSF, ISF, cellular models, organoids, and tissue samples

  • Fully immune-based platform: results are easily translatable to other immune-based platforms

  • Post-translational modification analysis available

  • Complete package: study design, data collection, data analysis and customized study report

  • Minimal sample amounts required 

 

Common Scientific ApplicationsProtein profiling service including data analysis

  • Biomarker discovery

  • Drug target discovery

  • Mode-of-Action analysis

  • Preclinical assessment and benchmarking of novel compounds

  • Cytokine profiling and immune response profiling 

  • Pathway profiling and pathway activity analysis 

  • Characterization and selection of cell culture or animal models 

  • Immune response profiling



Our Protein Biomarker Discovery and Development Pipeline

To enable Precision Medicine and to improve diagnostic research, we need techniques to discover and validate novel and more accurate biomarkers. We have built a broad biomarker development pipeline in Oncology, Infectious Diseases and Organ Failure. Our platform is also well suited to advance biomarker discovery across a broad range of other fields or applications, such as neurodegenerative diseases and aging. Our immune-based discovery service for protein biomarkers (scioDiscover) utilizes complex antibody microarrays covering crucial pathway proteins for multiple diseases as well as secreted proteins.  The results are easily translatable to other immune-based platforms for further validation and diagnostic use, such as ELISA, CLIA or LFDs. Thereby, our fully immune-based workflow reduces the cost and attrition rates of biomarker discovery studies.

With more than a decade of experience in protein biomarker discovery and validation, Sciomics is an excellent and dedicated partner for your biomarker project.

COVID-19 Biomarkers – Early Stratification for Better Health Care Protein biomarker discovery Covid19

In order to improve the situation in the COVID-19 pandemic, we conducted a biomarker study to support medical care and reduce the burden on the healthcare system. We discovered and systematically evaluated early biomarkers that predict the progression to severe or critical COVID-19 disease at symptom onset. Using the Sciomics antibody microarray platform, we identified plasma protein biomarkers that can predict severe COVID-19 disease during an early phase of SARS-CoV-2 infection. Evidence suggests that these markers are associated with mechanisms involved not only in the progression to severe COVID-19, but also in other infectious diseases. Early stratification of patients at high risk of developing severe or even critical disease could assist in making informed treatment and care decisions, ultimately improving medical interventions and reducing the burden on the healthcare system. 

 

For more information regarding our protein biomarker pipeline, please contact us.

 

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status
scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation. Features 1,300 highly relevant proteins are profiled in a single assay Phosphorylation status combined with protein expression levels…
Read more
scioUbi

scioUbi
Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse up to 1,000 proteins in a single assay.   Features Screen…
scioDiscover - Protein Profiling on the Expression Level

scioDiscover - Protein Profiling on the Expression Level
Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell Surface Marker and Cytokine Profiling

scioCD - Cell Surface Marker and Cytokine Profiling
Characterize Your Cell Type! Cell Composition Analysis in Tissue Samples CD-Marker Expression Profiles Increased Throughput at High Sensitivity Levels High Reproducibility       Our scioCD profiling service covers 260…
scioCyto : Cytokine Profiling

scioCyto : Cytokine Profiling
scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or…

COVID-19 related activities and services

covid 19 portfolio web

News

New Article | Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia

| September 2023 | New Article: Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Sciomics supported this study by scioCyto serum analysis in a mouse cancer model.

Taylor, J., Uhl, L., Moll, I. et al. Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Nat Cancer 4, 1544–1560 (2023). 
New Article | Rapid Diagnostic Platform for Personalized Vitamin B6 Detection in Erythrocytes

| July 2023 | New Article: Fiedler et al. developed a novel methodology for vitamin B6 diagnostics. We supported the project by the production of custom antibody microarray targeting signature human PLP-DE and testing respective samples.

Fiedler et al. Rapid Diagnostic Platform for Personalized Vitamin B6 Detection in Erythrocytes via PLP Cofactor Mimics (2023) ACS Chem Biol.
New Article | Microbiota Influences Chemotherapy in Pancreatic Cancer

| February 2023 | New Article: In the study Tintelnot et al. identified a microbiota-derived metabolite that has clinical implications in the treatment of pancreatic cancer. Sciomics supported the authors by a protein profiling study of tumours derived from a mouse model upon treatment with 3-IAA and Firinox.

Tintelnot et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168-174 (2023)
New Article | Predicting a severe Covid-19 disease

| April 2023 | New Article: In a protein biomarker development project initiated by Sciomics, we have identified protein biomarker panels predicting development of a severe Covid.19  disease.

Hufnagel K., Fathi A. et al. Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Communications Medicine 3,51 (2023)
New Sciomics Proteomics Research Blog has Launched!

Sciomics Protomics Research Blog

 

At Sciomics, we are dedicated to advancing healthcare through proteomics research. We are collaborating with research groups and big pharma, alongside our in-house biomarker research initiatives. To make this research more accessible to you, we are launching the new Sciomics science blog!

The first study we will feature was published this year in a journal in the Nature publishing group. It's a topic that affects us all. Any guesses? Stay tuned!

 

 

Testimonials

Dr. Matthew Wright

Chief Scientific Officer, Kinarus Therapeutics AG, Basel, Switzerland

"We are a small biotech company without our own wet labs. Sciomics recommended a UK CRO that performed cell culture experiments for our studies. Sciomics seamlessly coordinated the transfer of the biologic materials to their facility and performed the scioCD panel to characterize cell surface markers and cytokines in cell lines treated with our small molecule drug candidates. The Sciomics data were instrumental in supporting our IP protection strategy. Their advice was very helpful and they worked with us to extract the most out of the data. We are very satisfied and highly recommend the Sciomics platform and the team."

Product: scioCD

Kyriaki Barmpa

PhD Candidate, Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine, University of Luxembourg

"By collaborating with Sciomics, we conducted a detailed analysis of the proteome of striatum organoids, uncovering significant differences that further assisted our research. Their communication was highly efficient, and the results were delivered promptly."

Product: scioPhospho

BACK_TO_TOP